Featured Trial:
Lung Cancer Treatment

Featured Trial:
Colorectal Cancer Treatment

Featured Trial:
Melanoma Imaging

Featured Trial:
Head and Neck Cancer Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

March 22, 2025

Categories

The March 2025 News from ECOG-ACRIN blog is now available

March 17, 2025

Categories

News Stories

Stem cell transplant may not be necessary in first remission for patients with mantle cell lymphoma and undetectable MRD (features EA4151)

March 5, 2025

Categories

News Stories

WATCH: Dr. Kathy Miller on how the PATINA trial (AFT-38/PrE0111) shifts the paradigm in HER2+/ER- breast cancer treatment

March 5, 2025

Categories

News Stories

LISTEN: A JAMA Network Learning podcast interview with Dr. Anand Jillella, author of the newly published results of study EA9131 in JAMA Oncology

February 25, 2025

Categories

News Stories

Top trial results of 2024: A year of significant advancements in cancer treatment by ECOG-ACRIN and PrECOG

February 25, 2025

Categories

The February 2025 News from ECOG-ACRIN blog is now available

Posts

ECOG-ACRIN Cancer Research Group Follow 7,808 6,304

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

; ECOG-ACRIN Cancer Research Group @eaonc ·

14h 1905673797019009309

March is #KidneyCancerAwarenessMonth! Learn about #ClinicalTrial EA8211/SOAR, a study testing a new treatment approach for patients with #KidneyCancer that has spread to 2-5 other places in the body. View more info here: https://www.youtube.com/watch?v=v29UtHNXkDs&t=8s cc: @KidneyCancerJ, @kidneycan

Reply on Twitter 1905673797019009309 Retweet on Twitter 1905673797019009309 0 Like on Twitter 1905673797019009309 0 Twitter 1905673797019009309

; ECOG-ACRIN Cancer Research Group @eaonc ·

15h 1905666382517113045

#ClinicalTrial EA3202, led by @AartiBhatiaMD of @YaleCancer, aims to improve results for patients with advanced-stage #HeadAndNeckCancer by comparing several treatment approaches. Learn more: https://bit.ly/ea3202-study #HNCA #HNCASM

Reply on Twitter 1905666382517113045 Retweet on Twitter 1905666382517113045 0 Like on Twitter 1905666382517113045 0 Twitter 1905666382517113045

; ECOG-ACRIN Cancer Research Group @eaonc ·

16h 1905651288827691062

Do you have high-risk #SmolderingMultipleMyeloma? If so, you may be eligible for EAA173/DETER-SMM, a #ClinicalTrial exploring new #SMM treatment approaches. For more information, click here: https://bit.ly/eaa173detersmm

Reply on Twitter 1905651288827691062 Retweet on Twitter 1905651288827691062 0 Like on Twitter 1905651288827691062 0 Twitter 1905651288827691062

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).